Header Logo

Connection

Mohammed Rassool to Raltegravir Potassium

This is a "connection" page, showing publications Mohammed Rassool has written about Raltegravir Potassium.
Connection Strength

0,300
  1. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. J Acquir Immune Defic Syndr. 2018 08 15; 78(5):589-598.
    View in: PubMed
    Score: 0,155
  2. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 11; 4(11):e486-e494.
    View in: PubMed
    Score: 0,145
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.